Covid 19 Research using Clinical Trials (Home Page)
Report for D009196: Myeloproliferative Disorders NIH
(Synonyms: Myelop, Myeloproli, Myeloproliferati, Myeloproliferative Dis, Myeloproliferative Disorders)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (0)
| Name (Synonyms) | Correlation |
|---|
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005547 | Myeloproliferative disorder HPO | 1.00 |
| HP:0002664 | Neoplasm HPO | 0.30 |
There is one clinical trial.
Clinical Trials
1 Myeloproliferative Neoplasms (MPN) and COVID-19
An increased risk of both venous and arterial thromboembolism was noted in reports from SARS-CoV-2-infected patients in China and has been confirmed in autopsy findings from patients who experienced sudden death. Myeloproliferative Neoplasms (MPNs), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. It therefore follows that an underlying diagnosis of MPN may increase the risk of worse clinical outcomes and death during periods of active Covid-19 disease. This ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with MPN who develop Covid-19 disease.
NCT04385160 Myeloproliferative Neoplasm COVID MeSH:Myeloproliferative Disorders Neoplasms
HPO:Myeloproliferative disorder Neoplasm
Primary Outcomes
Description: Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism
Measure: pulmonary embolism (PE) Time: 2 and a half months
Secondary Outcomes
Description: Incidence of cases reporting at least one fatal or non fatal thrombotic event reported in therapy of MPN
Measure: fatal or non fatal thrombotic event Time: 2 and a half months
Description: Incidence of cases reporting at least one COVID-19 worsening outcome as Continuous Positive Airway Pressure (CPAP)
Measure: Continuous Positive Airway Pressure (CPAP) Time: 2 and a half months
Description: Incidence of cases reporting at least one COVID-19 worsening outcome as invasive ventilation
Measure: invasive ventilation Time: 2 and a half months
Description: Incidence of cases reporting at least one COVID-19 worsening outcome as Intensive Care Unit (ICU)
Measure: admission in Intensive Care Unit (ICU) Time: 2 and a half months
Description: incidence of death
Measure: death Time: 2 and a half months
Description: Type of treatments and interventions applied for MPN during COVID-19 and any change reported in therapy of MPN
Measure: treatments and interventions applied for MPN Time: 2 and a half months
Description: Type of treatments and interventions applied for COVID-19
Measure: treatments and interventions applied for COVID-19 Time: 2 and a half months
Description: Odds Ratios (ORs) of the outcome and 95% Confidence Intervals (CIs) associated with patients' characteristics and treatments
Measure: thrombotic events association to patients characteristic and treatments Time: 2 and a half months
HPO Nodes
Primary Outcomes
Description: Incidence of cases of MPN patients with COVID-19 experiencing pulmonary embolism
Measure: pulmonary embolism (PE) Time: 2 and a half monthsSecondary Outcomes
Description: Incidence of cases reporting at least one fatal or non fatal thrombotic event reported in therapy of MPN
Measure: fatal or non fatal thrombotic event Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as Continuous Positive Airway Pressure (CPAP)
Measure: Continuous Positive Airway Pressure (CPAP) Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as invasive ventilation
Measure: invasive ventilation Time: 2 and a half monthsDescription: Incidence of cases reporting at least one COVID-19 worsening outcome as Intensive Care Unit (ICU)
Measure: admission in Intensive Care Unit (ICU) Time: 2 and a half monthsDescription: incidence of death
Measure: death Time: 2 and a half monthsDescription: Type of treatments and interventions applied for MPN during COVID-19 and any change reported in therapy of MPN
Measure: treatments and interventions applied for MPN Time: 2 and a half monthsDescription: Type of treatments and interventions applied for COVID-19
Measure: treatments and interventions applied for COVID-19 Time: 2 and a half monthsDescription: Odds Ratios (ORs) of the outcome and 95% Confidence Intervals (CIs) associated with patients' characteristics and treatments
Measure: thrombotic events association to patients characteristic and treatments Time: 2 and a half months